182 related articles for article (PubMed ID: 33108799)
41. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.
Martyanov V; Kim GJ; Hayes W; Du S; Ganguly BJ; Sy O; Lee SK; Bogatkevich GS; Schieven GL; Schiopu E; Marangoni RG; Goldin J; Whitfield ML; Varga J
PLoS One; 2017; 12(11):e0187580. PubMed ID: 29121645
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
Elhai M; Boubaya M; Distler O; Smith V; Matucci-Cerinic M; Alegre Sancho JJ; Truchetet ME; Braun-Moscovici Y; Iannone F; Novikov PI; Lescoat A; Siegert E; Castellví I; Airó P; Vettori S; De Langhe E; Hachulla E; Erler A; Ananieva L; Krusche M; López-Longo FJ; Distler JHW; Hunzelmann N; Hoffmann-Vold AM; Riccieri V; Hsu VM; Pozzi MR; Ancuta C; Rosato E; Mihai C; Kuwana M; Saketkoo LA; Chizzolini C; Hesselstrand R; Ullman S; Yavuz S; Rednic S; Caimmi C; Bloch-Queyrat C; Allanore Y;
Ann Rheum Dis; 2019 Jul; 78(7):979-987. PubMed ID: 30967395
[TBL] [Abstract][Full Text] [Related]
43. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy.
Miyamae T; Yokoya S; Yamanaka H; Yokota S
Mod Rheumatol; 2014 Jul; 24(4):567-71. PubMed ID: 24252004
[TBL] [Abstract][Full Text] [Related]
44. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.
Fraticelli P; Gabrielli B; Pomponio G; Valentini G; Bosello S; Riboldi P; Gerosa M; Faggioli P; Giacomelli R; Del Papa N; Gerli R; Lunardi C; Bombardieri S; Malorni W; Corvetta A; Moroncini G; Gabrielli A;
Arthritis Res Ther; 2014 Jul; 16(4):R144. PubMed ID: 25007944
[TBL] [Abstract][Full Text] [Related]
45. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.
Griffiths B; Miles S; Moss H; Robertson R; Veale D; Emery P
J Rheumatol; 2002 Nov; 29(11):2371-8. PubMed ID: 12415594
[TBL] [Abstract][Full Text] [Related]
46. Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests.
Kloth C; Maximilian Thaiss W; Preibsch H; Mark K; Kötter I; Hetzel J; Nikolaou K; Henes J; Horger M
Rheumatology (Oxford); 2016 Oct; 55(10):1763-70. PubMed ID: 27330164
[TBL] [Abstract][Full Text] [Related]
47. Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review.
Sakai R; Kondo T; Kurasawa T; Nishi E; Okuyama A; Chino K; Shibata A; Okada Y; Takei H; Nagasawa H; Amano K
Clin Rheumatol; 2017 Oct; 36(10):2383-2392. PubMed ID: 28733791
[TBL] [Abstract][Full Text] [Related]
48. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
49. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
Smolen JS; Avila JC; Aletaha D
Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
[TBL] [Abstract][Full Text] [Related]
50. [Tocilizumab for refractory systemic juvenile idiopathic arthritis].
Lai JM; Wu FQ; Zhou ZX; Kang M; Huang XL; Su GX; Li SN; Zhu J; Wang XN
Zhonghua Er Ke Za Zhi; 2017 Nov; 55(11):830-834. PubMed ID: 29141313
[No Abstract] [Full Text] [Related]
51. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.
Streicher K; Sridhar S; Kuziora M; Morehouse CA; Higgs BW; Sebastian Y; Groves CJ; Pilataxi F; Brohawn PZ; Herbst R; Ranade K
Arthritis Rheumatol; 2018 Dec; 70(12):2087-2095. PubMed ID: 29956883
[TBL] [Abstract][Full Text] [Related]
52. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases.
Song ST; Kim JJ; Lee S; Kim HA; Lee EY; Shin KC; Lee JH; Lee KH; Choi ST; Cha HS; Yoo DH
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S64-S71. PubMed ID: 27462914
[TBL] [Abstract][Full Text] [Related]
54. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
[TBL] [Abstract][Full Text] [Related]
55. Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis.
Taniguchi T; Asano Y; Fukasawa T; Yoshizaki A; Sato S
J Dermatol; 2017 Aug; 44(8):967-971. PubMed ID: 28342234
[TBL] [Abstract][Full Text] [Related]
56. Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
Opoka-Winiarska V; Żuber Z; Alexeeva E; Chasnyk V; Nikishina I; Dębowska G; Smolewska E
Clin Rheumatol; 2018 Jul; 37(7):1807-1816. PubMed ID: 29654485
[TBL] [Abstract][Full Text] [Related]
57. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
58. HRCT in systemic sclerosis: correlation between respiratory functional indexes and extension of lung failure.
Gatta G; Di Grezia G; Iacomino A; Russo A; Petrillo M; Feragalli B; Cappabianca S; Grassi R
J Biol Regul Homeost Agents; 2013; 27(2):579-87. PubMed ID: 23830407
[TBL] [Abstract][Full Text] [Related]
59. Scleroderma in children.
Zulian F
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):576-595. PubMed ID: 29773274
[TBL] [Abstract][Full Text] [Related]
60. Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.
Salaffi F; Carotti M; Di Donato E; Di Carlo M; Ceccarelli L; Giuseppetti G
PLoS One; 2016; 11(3):e0149240. PubMed ID: 26930658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
